Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Products

Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States.

Financial terms of the deal were not disclosed.

“As we expand our US presence, we are excited to embrace this popular portfolio of ophthalmic products that are widely recognized for the difference they make in patients’ lives,” said Susan Benton, Théa’s General Manager, and head of the US business. “The acquisition of these products further demonstrates Théa’s commitment and mission to serve the doctors that treat anterior segment and ocular surface conditions. Our skilled and knowledgeable sales force is well positioned to increase awareness, drive growth, and expand accessibility for these widely utilized offerings.”

Under the deal, Théa acquired seven products including established glaucoma therapies Zioptan, Cosopt, Cosopt PF, Betimol, Azasite, Akten, and the ocular surface repair agent AcellFX. Detailed product information can be found here.

“The closing of this transaction bolsters Théa’s mission to share innovative treatments across a range of therapeutic areas, including glaucoma, dry eye, allergy and inflammation,” said Théa’s President, Jean-Frédéric Chibret. “It has been a pleasure to collaborate with Akorn throughout this process to ensure that its products are seamlessly transitioned and integrated into our portfolio and the marketplace. Ultimately, this will increase doctor and patient access to these brands—and to others as our offerings grow.”

Also this month, launch activities have begun for its evidence-based line of iVIZIA OTC products for dry eye and eyelid hygiene being distributed by Similasan Corporation. In addition, Théa filed its first new drug application (NDA) with the FDA for a version of the glaucoma treatment latanoprost on February 18, 2022.

During a short post-closing transition period, Akorn will provide services to Théa, with respect to business operations and management. Business will continue as usual, with Théa providing updates as needed to all key stakeholders.